Tianjin Development (HKG:0882) unit Lisheng Pharmaceutical subscribed for a total of 185 million yuan of investment products by Industrial Bank (SHA:601166), a Wednesday Hong Kong bourse filing said.
The eight agreements related to the investments, which were made to achieve a better return on idle funds, were entered into between March 31 and June 11.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.